---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-036224"
form_type: "8-K"
ticker: "KALV"
cik: "0001348911"
company_name: "KalVista Pharmaceuticals, Inc."
filed_at: "2024-02-14T23:59:59+00:00"
generated_at: "2026-06-06T02:08:26.125246+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.15
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# KalVista terminates $100M ATM sales agreement with Cantor Fitzgerald; no shares sold

## Summary
- Terminated Controlled Equity Offering Sales Agreement with Cantor, effective Feb 14, 2024.
- Agreement allowed up to $100M in common stock sales; company sold zero shares under it.
- Cantor waived notice period, making termination immediate upon close of business Feb 14.
- Termination has no effect on operations or capital; company retains other financing avenues.

## SEC filing metadata
- accession: 0001193125-24-036224
- form_type: 8-K
- ticker: KALV
- cik: 0001348911
- company_name: KalVista Pharmaceuticals, Inc.
- filed_at: 2024-02-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.15
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 1.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1348911/000119312524036224/0001193125-24-036224-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1348911/000119312524036224/d771919d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-036224
- JSON: https://secwatch.observer/filing/0001193125-24-036224.json
- Plain text: https://secwatch.observer/filing/0001193125-24-036224.txt

## Key facts
- Material Agreements
  KalVista Pharmaceuticals, Inc. terminated Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. valued at no shares sold under the agreement; aggregate offering price up to $100.0 million (effective 2024-02-14).
  - Action: termination
  - Agreement: atm program
  - Counterparty: Cantor Fitzgerald & Co.
  - Value: no shares sold under the agreement; aggregate offering price up to $100.0 million
  - Effective: 2024-02-14
  source text: On February 14, 2024, KalVista Pharmaceuticals, Inc. (the “Company”) delivered a written notice of termination (the “Termination Notice”) of that certain Controlled Equity Offering Sales Agreement (the “Sales Agreement”), dated May 21, 2021, by and between the Company and Cantor Fitzgerald & Co., as sales agent (“Cantor”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1348911/000119312524036224/0001193125-24-036224-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.